Dimensional Fund Advisors LP Grows Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Dimensional Fund Advisors LP increased its stake in IQVIA Holdings Inc. by 2.9%, owning approximately 1.43 million shares worth $251.85 million as of the most recent reporting period.
• Analysts have varied reactions, with UBS Group raising its target price from $185 to $225, while HSBC downgraded its rating from "buy" to "hold" and reduced its target price from $260 to $160.
• IQVIA reported earnings of $2.81 per share for the last quarter, surpassing estimates, and projected FY 2025 guidance between $11.750 and $12.050 EPS.

Dimensional Fund Advisors LP increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,428,561 shares of the medical research company's stock after acquiring an additional 40,699 shares during the period. Dimensional Fund Advisors LP owned about 0.83% of IQVIA worth $251,852,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. American National Bank & Trust acquired a new stake in shares of IQVIA in the 1st quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in IQVIA in the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on IQV shares. UBS Group increased their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research note on Friday, May 23rd. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Mizuho increased their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Finally, Cowen reiterated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Stock Performance

Shares of IQVIA stock traded up $5.5970 on Friday, reaching $190.9870. 1,619,418 shares of the company traded hands, compared to its average volume of 1,441,272. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a 50 day moving average of $173.70 and a 200 day moving average of $168.26. The firm has a market capitalization of $32.47 billion, a PE ratio of 27.64, a PEG ratio of 2.10 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the prior year, the firm earned $2.64 EPS. The company's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.